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Abstract
Background
Post-transfusion hepatitis occurs even with stringent donor selection criteria and screening for hepatitis B surface antigen (HBsAg). The objective of  
this study was to determine the prevalence of  antibody to hepatitis B core antigen (anti-HBc) in HBsAg-negative blood donors.
Methods
This was a cross-sectional study in which 200 HBsAg-negative blood donors were recruited. Screening for viral markers was done using both a rapid test 
kit and enzyme-linked immunosorbent assay (ELISA) for anti-HBc IgM. Quantitative and qualitative analysis of  anti-HBc IgM was done by “capture” 
enzyme immunoassay using DIA.PRO HBc IgM test kits. The other viral markers were investigated using one step cassette style HBV tests. SPSS 
version 16 was used for data analysis. A P-value of  0.05 or less was considered significant.
Results
There were 190 male (95%) and 10 female (5%) blood donors, with a mean age of  31.7 ± 7.9 years. The prevalence of  anti-HBc IgM was 4%. The other 
viral markers (HBeAg, anti-HBeAg, anti-HBs and total anti-HBc) had a prevalence of  1.5%, 23%, 2.5%, and 32.5%, respectively.
Conclusions
The prevalence of  anti-HBc IgM in this study was high, and this supports the fact that screening blood donors for HBsAg alone is not sufficient to 
prevent transmission of  HBV.
Introduction
Transfusion-associated hepatitis B virus infection (TAHBV) 
continues to be a major problem in developing countries, 
even after the adoption of  mandatory screening for 
hepatitis B surface antigen (HBsAg) by the enzyme-linked 
immunosorbent assay (ELISA).1 The burden of  Hepatitis B 
virus (HBV) infection is heavy in most developing countries, 
particularly in rural areas; this burden is compounded by 
the high cost of  prevention, management, and treatment.2 
Transmission of  this virus is common through blood 
transfusion. Other modes of  transmission include sexual 
contact, close interpersonal contact through blood and 
body fluids, mother-to-child (vertical), intravenous drug use 
(IVDU), and unsafe traditional practices including tattoos, 
ear piercing, circumcision, and traditional uvulectomy. 
Detection of  HBsAg in the blood is a diagnostic marker for 
infection with HBV. In blood banks, screening for HBsAg 
is carried out routinely to detect current or previous HBV 
infection. Occult HBV infection is defined as the presence 
of  HBV DNA in blood or liver tissues in patients negative 
for HBsAg but who may or may not be positive for HBV 
antibodies.3 Thus, the absence of  HBsAg in the blood of  
apparently healthy individuals may not indicate the absence 
of  circulating HBV, and blood containing antibody to 
hepatitis B core antigen (anti-HBc) without detectable 
HBsAg might be infectious.1 A window period exists, which 
represents a carrier state of  the disease, and this poses a risk 
of  TAHBV. During this window period, detection of  anti-
HBc serves as a useful serological marker for hepatitis B 
infection. The IgM class of  anti-HBc is the first to appear 
and indicates a recent infection, while IgG anti-HBc appears 
later during the infection and points to a past HBV infection.4 
The use of  HBsAg and anti-HBc screening tests has been 
the basis of  HBV screening in many countries, and this has 
significantly reduced but not eliminated TAHBV.5 Anti-HBc 
has been found to be an excellent indicator of  occult HBV 
infection during the window period after the disappearance 
of  HBsAg.6-8 It has been observed that a negative screening 
test for HBsAg does not rule out the transmission of  HBV 
in donors, as they might be in the window period and the 
detection of  the IgM-type anti-HBc serves as a useful 
serological marker during this period.9
HBV infection, with its associated sequelae, is a disease of  
major public health importance, being the tenth leading cause 
of  death globally and accounting for 500,000 to 1.2 million 
deaths each year.10-12 Approximately 15% to 40% of  infected 
patients will develop cirrhosis, liver failure, or hepatocellular 
carcinoma.13,14 Nigeria, the most populous nation in Africa, 
is considered hyperendemic for HBV infection, with a 
prevalence of  HBsAg in the adult population ranging 
between 5% and 25%.15-21 Nigeria, being a developing 
country with high level of  poverty, cannot afford DNA 
testing of  all collected units of  blood, despite DNA testing 
serving as the only possibility of  achieving a near-zero risk 
of  TAHBV.6
The objective of  this study was to help elucidate the 
seroprevalence of  anti-HBc (IgM) among blood donors 
negative for HBsAg in Ilorin, north-central Nigeria, 
which is a possible basis for advocating for compulsory 
implementation of  screening for anti-HBc as part of  routine 
blood donor screening.
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Sixty-five participants (32.5%) were positive for total anti-
HBc, indicating a past exposure to HBV. Positivity in first-
time donors was not significant (P > 0.05). There was also no 
significant association between total anti-HBc-positivity and 
the frequency of  donation, gender, and marital status.
The quantitative analysis for HBc IgM revealed that 5 
donors had antibody levels greater than 10.00 Paul Ehrlich 
International units per mL (PEI U/mL); these were 
considered positive. However, 15 donors in the grey area 
were traced and retested. Upon retesting, 12 had levels less 
than 5 PEI U/mL and were considered negative. Three still 
remained within the 5- to 10-PEI U/mL grey area after 
retesting and were therefore considered positive according 
to the manufacturer’s instructions. The remaining 180 
donors had HBc IgM levels less than 5.00 PEI U/mL and 
were considered negative. Overall, 8 (4.0%) of  the donors 
were found to be positive for anti-HBc IgM alone (Table 
2) and all were replacement blood donors. Only one female 
donor showed positivity for anti-HBc IgM. Ninety-three 
(46.5%) of  the donors were positive for at least one of  the 
viral markers.
There was no significant relationship between the viral 
marker positivity and the type of  blood donors (voluntary 
vs family replacement); similarly, there was no significant 
relationship between viral marker positivity and frequency 
of  donation, as shown in Table 4.
Methods
This was a descriptive cross-sectional study carried out 
among blood donors at the University of  Ilorin Teaching 
Hospital (UITH), Ilorin, between May and November 2013.
The minimum sample size for this study was determined 
using Fisher’s formula22 for estimating sample size to 
determine the prevalence or proportion of  a factor where 
the population is greater than 10,000.28,32
A sample size of  174 was calculated as the the minimum to 
estimate prevalence with 95% confidence that the result is 
within 5% of  the true prevalence. However, a final total of  
200 respondents were sampled during the study. 
Inclusion criteria were age between 17 and 65 years; 
haemoglobin concentration (Hb) greater than 13.5 g/dL 
in males and greater than 12.5 g/dL in females; no blood 
donation in the previous 3 months for males and 4 months 
for females; and negative screening for HBsAg, hepatitis 
C virus (HCV), syphilis, and human immunoficiency virus 
(HIV) using rapid test kits.
Ethical clearance was obtained from the UITH Ethical 
Research Committee. Written informed consent was obtained 
from all participants. Questionnaires were administered 
and samples collected from those who met the inclusion 
criteria. Sociodemographic data, such as age, gender, marital 
status, religion, occupation, and level of  education were 
noted. History of  jaundice, surgeries, transfusion, sexually 
transmitted infection, tattooing, and IVDU, as well as general 
physical examination findings, were recorded.
Under aseptic technique, 5 mL of  venous blood was collected 
into a plain vacuum blood collection tube (Micropoint 
Diagnostics, Santa Clara, CA, USA). The blood was allowed 
to clot and retract at room temperature. Sera were separated 
by centrifugation at 3000 rpm for 5 minutes. The supernatant 
sera were aspirated into vials and preserved at −200°C 
until analysed. ELISA for anti-HBc IgM quantitative and 
qualitative determination was done with DIA.PRO HBc IgM 
test kits (Diagnostics Bioprobes, Milan, Italy), following the 
manufacturer’s instructions. According to the manufacturer’s 
data sheet, the sensitivity and specificity for this test method 
were 98%  and 99%, respectively.
The test for the other viral markers (anti-HBs, HBeAg, anti-
HBe, and anti-HBc total) were done using one step cassette 
style HBV tests (Atlas Link, Manassas, VA, USA). The one 
step cassette style HBV test is a rapid test based on the 
principle of  immunoassay combined with conjugated colloid 
gold technology. According to the manufacturer’s data sheet, 
sensitivity is up to 1 ng/mL, while specificity is 99.8%.
Data were analysed using SPSS version 16 (SPSS Inc., 
Chicago, IL, USA). Continuous variables were expressed as 
mean ± standard deviation (SD). Comparison of  categorical 
data was done using the chi-square and Fisher’s exact tests. A 
P-value of  0.05 or less was considered statistically significant.
Results
Two hundred HBsAg-negative blood donors at the blood 
donor unit of  UITH were recruited for this study. The 
mean age of  the participants was 31.7 ± 7.9 years. Nearly 
half  (46.5%) of  the donors were in the 26- to 34-year-old 
age group. Five percent of  donors were female, with a male 
to female ratio of  19:1. The majority (97.5%) were family 
replacement donors, of  which most (88%) were first-time 
donors. 
Table 1 shows that out of  the 200 HBsAg-negative blood 
donors recruited into this study, only 5 (2.5%) were positive 
for anti-HBs, of  which 4 (80%) were in the 17- to 34-year 
age group. Of  the 5 anti-HBs-positives, four were as a result 
of  immunity from natural infection, while the remaining one 
was from vaccination.
Table 1: Overall prevalence of hepatitis B virus markers 
among blood donors






















Ql = qualitative assay; Qn = quantitative assay
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Positive 0 (0.0) 3 (100.0)
0.00 0.00 to 119.95 1.00
Negative 5 (2.5) 192 (97.5)
Anti-HBs
Positive 0 (0.0) 5 (100.0)
0.00 0.00 to 60.90 1.00
Negative 5 (2.6) 190 (74.4)
Anti-HBe
Positive 0 (0.0) 46 (100.0)
0.00 0.00 to 3.94 0.591
Negative 5 (3.2) 149 (96.8)
Total anti-HBc
Positive 3 (4.6) 62 (95.4)
3.22 0.42 to 28.33 0.331
Negative 2 (1.5) 133 (98.5)
*Fisher’s exact test was used to determine P-values
: ype of donor and viral markers
Table 3: Relationship between total anti-HBc status and donor types
Variable
Anti-HBc total
Odds ratio 95% Confidence 
interval
P-value
Positive (%) Negative (%)
Type of donor
Voluntary 3 (60.0) 2 (40.0)
3.22 0.42 to 28.33 0.33*Family 
replacement 5 (2.5) 192 (97.5)
Donor 
experience
First donation 58 (32.3) 118 (67.0)
1.19 0.43 to 3.38 0.71
Repeat donor 7 (29.2) 17 (70.8)
*Fisher’s exact test was used to determine P-value
le 3: Total anti-HBc status in rela ion to donor type and experience











Positive Negative Positive Negative Positive Negative Positive Negative
17 to 25 2 (4.3) 45 (95.7) 11 (23.4) 36 (76.6) 2 (4.3) 45 (95.7) 14 (7.0) 33 (16.5)
26 to 34 1 (1.1) 92 (98.9) 20 (21.5) 73 (78.5) 2 (2.2) 91 (97.8)
29 
(14.5) 64 (32)
35 to 43 0 (0.0) 44 (100.0) 13 (29.5) 31 (70.5) 1 (2.3) 43 (97.7) 16 (36.4) 28 (63.6)
44 to 52 0 (0.0) 13 (100.0) 2 (15.4) 11 (84.6) 0 (0.0) 13 (100.0) 4 (30.8) 9 (69.2)
≥ 53 0 (0.0) 3 (100.0) 0 (0.0) 3 (100.0) 0 (0.0) 3 (100.0) 2 (66.7) 1 (33.3)
Total 3 (1.5) 197 (98.5) 0.87 46 (23) 154 (77) 0.64 5 (2.5) 195 (97.5) 0.90 65 (32.5) 135 (67.5) 0.71
 f epatitis B viral markers by age group
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Discussion
The safety of  blood products is one of  the major concerns 
in transfusion medicine. Although the incidence of  
transfusion-transmitted HBV has steadily reduced over 
the last four decades, HBV still remains the most frequent 
transfusion-transmitted viral infection.23-26 HBsAg detection 
is presently the only diagnostic screening test for HBV 
infection identification in blood transfusion centres in 
Nigeria. Following infection by HBV, the first serological 
marker in the blood is HBV DNA, followed by HBsAg, 
DNA polymerase, and then hepatitis B e antigen (HBeAg). 
Thereafter, the anti-HBc antibody, anti-HBe antibody, and 
anti-HBs antibody appear.
From this study, 97.5% of  the blood donors were family 
replacement donors, which is similar to the 93.2% found in 
the study by Gulia et al. in Andhra Pradesh, India.27 This is 
in contrast to the study by Lavanya et al., where replacement 
donors made up only 14% the donor population.28 This 
observed difference could be a result of  differences in 
awareness levels regarding voluntary blood donation.
The transmission of  HBV infection following transfusion 
of  HBsAg-negative blood containing anti-HBc was first 
described in the Western world. Cases have also been 
reported of  some blood derivates negative for HBsAg but 
positive for anti-HBc, which were transmitted to recipients 
both after transfusion and after transplantation of  organs.29,30 
In a study carried out by Sodhi et al., 6% of  cancer patients 
were shown to develop post-transfusion hepatitis and their 
corresponding blood donors, on retesting their stored 
samples, were positive for anti-HBc and HBV DNA.31
In a study by Salawu et al. in Ile Ife, Nigeria, a prevalence 
of  4.4% was reported for anti-HBc.32 Ramezani et al.33 and 
Sofian et al.34 both reported prevalence rates of  2.1%, but 
without detection of  HBV DNA. A serological pattern of  
anti-HBc as a sole marker is not infrequent. In another study 
among 545 Iranian blood donors, 8% of  donors were found 
to be positive for isolated anti-HBc.35 However, despite 
non-detection of  HBV DNA in the serum, there have been 
reports of  post-transfusion HBV infection in recipients of  
blood positive for anti-HBc alone.36
The overall prevalence of  anti-HBc in this study was found 
to be 32.5% for total anti-HBc. This is higher than the 10.5% 
reported by Lavanya et al.28 in India, and the 16.6% reported 
by Said et al.37 These differences could be the result of  the 
endemicity of  HBV infection in Nigeria.17 This, however, is 
in contrast to the reports on  total anti-HBc in Europe and 
North America, with prevalence rates of  0.07% and 1.5%, 
respectively.38 There is low endemicity in these regions and 
the stringent donor selection criteria, high literacy rates, 
greater availability of  voluntary donors, and differences in 
sociocultural practices could account for this.
In Nigeria, the seroprevalence of  anti-HBc antibody is 
quite high when compared to Western countries, and hence 
screening of  donor blood for total anti-HBc may not be 
practically important and cannot be a criterion to discard 
blood units. In this study, just 4 (6.1%) of  the donors who 
tested positive for total anti-HBc had evidence of  immunity 
from natural infection with HBV, thus giving a prevalence 
of  6.1% of  anti-HBs in donors positive for total anti-HBc. 
This study shows that 4.6% of  the blood donors had positive 
anti-HBc and anti-HBs. This is, however, lower than the 6.3% 
found in a study by Ashshi in Saudi Arabia.39 In that study, 
donors were further tested for HBV DNA and 3.2% were 
found to be positive. Lavanya et al.28 found a prevalence of  
3.0% anti-HBs in total anti-HBc-positive donors. This was 
in contrast with a study conducted in Iran (which showed a 
higher prevalence rate of  37.5% for both anti-HBc and anti-
HBs) and the 40.3% prevalence found in a study by Said et 
al.30 These higher rates could be the result of  past infections 
or carrier states. Anti-HBc IgG may remain positive for 
life in an affected individual, although the individual has a 
protective level of  anti-HBs, and therefore positivity of  anti-
HBc IgG does not necessarily mean that the blood of  such 
donors is infectious.
In the present study, the prevalence of  anti-HBc IgM alone 
was found to be 4.0%. This was similar to findings of  4.3% 
and 4.8% in Ecuador and Brazil among potential blood 
donors,9 but slightly lower than  the findings of  Japhet et 
al.8 and Lavanya et al.,28 who found prevalence rates of  
5.4% and 5.5%, respectively. Furthermore, our finding of  
4.0% is lower than the 18.1% that was reported for isolated 
anti-HBc IgM by Jeremiah et al.40 in the semi-arid region of  
Nigeria. A Lebanese study also demonstrated that 22.0% of  
blood donors screened for HBV markers were positive for 
anti-HBc alone.41 This marked difference could be a result 
of  geographical location, different sociocultural practices, 
marital practices, and the sensitivity of  the test kits used. 
The finding of  anti-HBc IgM alone may be a result of  
the presence of  anti-HBc IgM during the window period 
following acute HBV infection, infection with HBV without 
persistent viraemia, remote infection with persistent occult 
infection, or the presence of  a vaccine escape mutant not 
detected by most of  the currently available HBsAg detection 
tests. Considering the above factors, blood from such donors 
might be infectious. Previous studies have also demonstrated 
the presence of  HBV DNA in blood postive for only anti-
HBc among the other viral markers. It has been observed 
that the screening tests for detection of  HBsAg do not rule 
out the possibility of  HBV transmission, as the donor might 
be in the window period, and detection of  anti-HBc would 
serve as a useful serologic marker during this period.
The major limitation to this study is the lack of  facilities for 
HBV DNA testing to confirm the presence of  occult HBV 
infection in those blood donors who were positive for anti-
HBc IgM alone. This is due to the high cost and the expertise 
required to carry out this test. Additionally, anti-HBs titre 
quantification was not carried out to detect if  those who 
developed the antibody from natural infection were indeed 
immune.
Conclusions
There is potentially a substantial risk of  HBV transmission 
despite HBsAg testing, and this is an important message 
for clinicians deciding to transfuse blood. The usefulness 
of  screening for anti-HBc as an additional screening test 
to improve the safety of  the blood supply in Nigeria needs 
further studies. Though there is a paucity of  similar studies 
in the country, a nationwide multicentre study should 
determine whether screening for anti-HBc in addition to 
HBsAg detection, and introduction of  PCR, are necessary.
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